JP7484027B2 - 皮下注射のための抗ｉｆｎａｒ１投薬計画 - Google Patents

皮下注射のための抗ｉｆｎａｒ１投薬計画 Download PDF

Info

Publication number
JP7484027B2
JP7484027B2 JP2023562678A JP2023562678A JP7484027B2 JP 7484027 B2 JP7484027 B2 JP 7484027B2 JP 2023562678 A JP2023562678 A JP 2023562678A JP 2023562678 A JP2023562678 A JP 2023562678A JP 7484027 B2 JP7484027 B2 JP 7484027B2
Authority
JP
Japan
Prior art keywords
anifrolumab
dose
patients
ifngs
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023562678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511227A (ja
Inventor
リンドホルム，カタリーナ
リン チア，イェン
トゥマラ，ラジェンドラ
ロスコス，ロリン
アルムクヴィスト，ヨアキム
ルーセ，トマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7484027(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2024511227A publication Critical patent/JP2024511227A/ja
Priority to JP2024074264A priority Critical patent/JP2024102205A/ja
Application granted granted Critical
Publication of JP7484027B2 publication Critical patent/JP7484027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Devices For Medical Bathing And Washing (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2023562678A 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画 Active JP7484027B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074264A JP2024102205A (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US63/178,739 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US63/245,285 2021-09-17
US202163272851P 2021-10-28 2021-10-28
US63/272,851 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074264A Division JP2024102205A (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画

Publications (2)

Publication Number Publication Date
JP2024511227A JP2024511227A (ja) 2024-03-12
JP7484027B2 true JP7484027B2 (ja) 2024-05-15

Family

ID=81750490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023562678A Active JP7484027B2 (ja) 2021-04-23 2022-04-21 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024074264A Pending JP2024102205A (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074264A Pending JP2024102205A (ja) 2021-04-23 2024-05-01 皮下注射のための抗ｉｆｎａｒ１投薬計画

Country Status (25)

Country Link
US (4) US20220340669A1 (enExample)
EP (2) EP4306541A3 (enExample)
JP (2) JP7484027B2 (enExample)
KR (2) KR20250092298A (enExample)
CN (2) CN120392997A (enExample)
AU (2) AU2022260531B2 (enExample)
BR (1) BR112023021761A2 (enExample)
CA (1) CA3216387A1 (enExample)
CL (1) CL2023003114A1 (enExample)
CO (1) CO2023015498A2 (enExample)
DK (1) DK4114465T5 (enExample)
ES (1) ES2963757T3 (enExample)
FI (1) FI4114465T3 (enExample)
HR (1) HRP20231255T1 (enExample)
HU (1) HUE063562T2 (enExample)
IL (1) IL307748A (enExample)
LT (1) LT4114465T (enExample)
MX (1) MX2023012465A (enExample)
PL (1) PL4114465T3 (enExample)
PT (1) PT4114465T (enExample)
RS (1) RS64821B1 (enExample)
SI (1) SI4114465T1 (enExample)
SM (1) SMT202300382T1 (enExample)
TW (1) TW202317182A (enExample)
WO (1) WO2022223714A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781705B1 (en) * 2004-06-21 2014-10-08 Medarex, L.L.C. Interferon alpha receptor i antibodies and their uses
US20250002590A1 (en) * 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508864A (ja) 2004-06-21 2008-03-27 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
JP2015526391A (ja) 2012-06-13 2015-09-10 メディミューン，エルエルシー 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2018523676A (ja) 2015-08-19 2018-08-23 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 安定な抗ｉｆｎａｒ１製剤
WO2020165437A1 (en) 2019-02-15 2020-08-20 Astrazeneca Ab Type i interferon-mediated disorders
JP2021515538A (ja) 2018-09-18 2021-06-24 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DK1711207T3 (da) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha-antistoffer og anvendelse heraf
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2008093166A2 (en) 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
ES2542836T3 (es) 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
CN101909444B (zh) 2007-11-05 2013-09-18 米迪缪尼有限公司 硬皮病治疗方法
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
ES2613055T3 (es) 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
AU2021279277A1 (en) 2020-05-29 2023-02-02 Astrazeneca Ab Treatment of cardiometabolic disease with inhibitors of type I interferon signalling
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
US20240327529A1 (en) 2020-11-18 2024-10-03 Astrazeneca Ab Steroid sparing
LT4114465T (lt) 2021-04-23 2023-11-10 Astrazeneca Ab Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
US20250002590A1 (en) 2021-04-23 2025-01-02 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508864A (ja) 2004-06-21 2008-03-27 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
JP2015526391A (ja) 2012-06-13 2015-09-10 メディミューン，エルエルシー 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2018523676A (ja) 2015-08-19 2018-08-23 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 安定な抗ｉｆｎａｒ１製剤
JP2021515538A (ja) 2018-09-18 2021-06-24 アイ−エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
WO2020165437A1 (en) 2019-02-15 2020-08-20 Astrazeneca Ab Type i interferon-mediated disorders

Also Published As

Publication number Publication date
US20240360231A1 (en) 2024-10-31
CN120514844A (zh) 2025-08-22
CL2023003114A1 (es) 2024-04-19
US20220340669A1 (en) 2022-10-27
WO2022223714A1 (en) 2022-10-27
JP2024511227A (ja) 2024-03-12
US20230365698A1 (en) 2023-11-16
EP4306541A2 (en) 2024-01-17
MX2023012465A (es) 2024-04-04
CO2023015498A2 (es) 2023-11-30
SMT202300382T1 (it) 2024-01-10
BR112023021761A2 (pt) 2023-12-26
PT4114465T (pt) 2023-11-03
DK4114465T5 (da) 2024-07-22
HUE063562T2 (hu) 2024-01-28
AU2022260531B2 (en) 2024-03-07
AU2022260531A1 (en) 2023-11-30
PL4114465T3 (pl) 2024-04-08
AU2022260531A9 (en) 2023-12-07
KR20230166134A (ko) 2023-12-06
JP2024102205A (ja) 2024-07-30
AU2024201743A1 (en) 2024-04-04
CN120392997A (zh) 2025-08-01
IL307748A (en) 2023-12-01
EP4114465A1 (en) 2023-01-11
TW202317182A (zh) 2023-05-01
HRP20231255T1 (hr) 2024-02-02
RS64821B1 (sr) 2023-12-29
US12060429B2 (en) 2024-08-13
LT4114465T (lt) 2023-11-10
ES2963757T3 (es) 2024-04-01
CA3216387A1 (en) 2022-10-27
FI4114465T3 (fi) 2023-10-31
SI4114465T1 (sl) 2023-11-30
KR20250092298A (ko) 2025-06-23
EP4306541A3 (en) 2024-03-27
DK4114465T3 (da) 2023-10-30
EP4114465B1 (en) 2023-08-30
US20240400699A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
JP7484027B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
KR20230082659A (ko) 루푸스에서의 발적의 치료
US20250002590A1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
US20250002589A1 (en) Treatment of cutaneous lupus erythematous
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции
KR20240038773A (ko) 루푸스의 치료
CN121127499A (zh) 狼疮的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231012

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240501

R150 Certificate of patent or registration of utility model

Ref document number: 7484027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150